The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.
The FDA approved the Amplatzer PFO Occluder device to reduce stroke risk in patients who have had a stroke from a blood clot passing through a patent foramen ovale.
The FDA approved the Amplatzer PFO Occluder device to reduce stroke risk in patients who have had a stroke from a blood clot passing through a patent foramen ovale.
The FDA has approved class-wide labeling changes for all prescription testosterone products with information regarding the risks of abuse and dependence.
The FDA has approved class-wide labeling changes for all prescription testosterone products with information regarding the risks of abuse and dependence.
The FDA has approved class-wide labeling changes for all prescription testosterone products with information regarding the risks of abuse and dependence.
The FDA approved a new method of administering treatment for patients with wet age-related macular degeneration and macular edema following retinal vein occlusion.
